Critical evaluation of the biological role of IgM in cerebrospinal fluid in inflammatory and other diseases of the nervous system
Language English Country United States Media print
Document type Journal Article
PubMed
17176772
DOI
10.1007/bf02931596
Knihovny.cz E-resources
- MeSH
- Biomarkers MeSH
- Immunoglobulin M blood cerebrospinal fluid MeSH
- Humans MeSH
- Linear Models MeSH
- Cerebrospinal Fluid chemistry cytology immunology MeSH
- Nervous System Diseases blood cerebrospinal fluid immunology MeSH
- Predictive Value of Tests MeSH
- Cerebrospinal Fluid Proteins chemistry MeSH
- Inflammation MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Immunoglobulin M MeSH
- Cerebrospinal Fluid Proteins MeSH
In a group of 10,156 patients with neurological diseases, the IgM level was assessed (using laser nephelometry) both in cerebrospinal fluid (CSF) and serum; concentration of other 17 protein fractions was also simultaneously determined: albumin, immunoglobulins, acute phase reactants, complement components, apolipoproteins, proteinase inhibitors and alpha1-microglobulin. Total protein, element counts and glucose level were also evaluated. In patients with normal CSF findings, only limited statistically significant correlations were demonstrated between IgM and other CSF protein fractions while, in the group of patients with pathological CSF findings, significant correlations were found between CSF(IgM) and other immunoglobulins, complement fractions and the rate of intrathecal synthesis of immunoglobulins. Correlations were also found between CSF(IgM) and CSF antithrombin-III and alpha1-microglobulin. Correlations between CSF(IgM) and CSF apolipoproteins support the theory of CNS tissue destruction whenever the concentration of CSF apolipoproteins is elevated. Our data substantially contribute to establishing the diagnosis in patients with neurological diseases; simultaneous measurement of a high number of CSF proteins is becoming inevitable for a reasonable assessment of the CSF Protein Status.
See more in PubMed
Acta Neurol Scand. 1987 Mar;75(3):201-8 PubMed
Clin Chim Acta. 2003 Aug;334(1-2):107-10 PubMed
J Neurol Neurosurg Psychiatry. 1985 Aug;48(8):807-13 PubMed
Alzheimer Dis Assoc Disord. 1990 Summer;4(2):79-86 PubMed
J Neurol. 2003 Mar;250(3):371-2; author reply 372 PubMed
Adv Clin Chem. 2001;36:1-62 PubMed
J Neurol. 1980;224(2):89-99 PubMed
J Med Virol. 1986 Feb;18(2):149-58 PubMed
J Neuroimmunol. 1988 Dec;20(2-3):315-6 PubMed
Acta Neurol Scand. 2005 Aug;112(2):97-102 PubMed
J Neurol Sci. 1987 Feb;77(2-3):125-35 PubMed
Acta Neurol Scand. 1987 May;75(5):328-31 PubMed
Acta Neurol Scand. 2001 Aug;104(2):72-7 PubMed
Clin Chem Lab Med. 2003 Mar;41(3):331-7 PubMed
Sb Lek. 2003;104(1):1-12 PubMed
Folia Microbiol (Praha). 2003;48(6):849-55 PubMed
Fortschr Med. 1984 Sep 27;102(36):903-5 PubMed
Folia Microbiol (Praha). 2003;48(6):839-47 PubMed
Acta Cytol. 2001 Jan-Feb;45(1):51-9 PubMed
Acta Neurol Scand. 2000 Feb;101(2):89-94 PubMed
J Neuroimmunol. 1986 Oct;12(4):299-310 PubMed
Analysis of cerebrospinal fluid cell populations with monoclonal antibodies